Company intelligence / Profile preview

Oxalide

Montreal, Quebec, Canadagithub.com ↗

Ownership: Private
Development stage: Other

Overview

Oxalys Pharmaceuticals has developed a proprietary cell-based screening platform to identify compounds that can halt or reverse the progression of neurodegenerative diseases. Their lead candidate, OXD4, has shown strong preclinical efficacy and received FDA orphan drug designation for Huntington's disease. Clinical trials have not yet begun.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Michael J Fox Foundation (funding/support)National Research Council of Canada (funding/support)Academic and industry partners on contract research services

Beyond the preview

Go deeper on Oxalide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxalide.

Explore the full profile